CU20140068A7 - Triazolopiridinas sustituidas - Google Patents

Triazolopiridinas sustituidas

Info

Publication number
CU20140068A7
CU20140068A7 CU2014000068A CU20140068A CU20140068A7 CU 20140068 A7 CU20140068 A7 CU 20140068A7 CU 2014000068 A CU2014000068 A CU 2014000068A CU 20140068 A CU20140068 A CU 20140068A CU 20140068 A7 CU20140068 A7 CU 20140068A7
Authority
CU
Cuba
Prior art keywords
compounds
substituted
triazolopiridins
preparing
formula
Prior art date
Application number
CU2014000068A
Other languages
English (en)
Inventor
Volker Schulze
Dirk Kosemund
Antje Margret Wengner
Gerhard Siemeister
Detlef Stöckigt
Michael Bruening
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20140068A7 publication Critical patent/CU20140068A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Compuestos de triazolopiridina sustituida de la fórmula general (I) EsESPACIO PARA FÓRMULA, donde R^1, R^2, R^3, R^4, R^5 tienen los valores que se definen en la descripción y en las reinvindicaciones. Métodos para preparar dichos compuestos. Composiciones y combinaciones farmacéuticas que comprenden dichos compuestos. Uso de dichos compuestos para preparar una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad. Compuestos intermediarios útiles para preparar dichos compuestos.
CU2014000068A 2011-12-12 2014-06-12 Triazolopiridinas sustituidas CU20140068A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11193011 2011-12-12
PCT/EP2012/074978 WO2013087579A1 (en) 2011-12-12 2012-12-10 Substituted triazolopyridines and their use as ttk inhibitors

Publications (1)

Publication Number Publication Date
CU20140068A7 true CU20140068A7 (es) 2014-12-26

Family

ID=47427291

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2014000068A CU20140068A7 (es) 2011-12-12 2014-06-12 Triazolopiridinas sustituidas

Country Status (39)

Country Link
US (1) US9663510B2 (es)
EP (1) EP2791136B1 (es)
JP (1) JP6181664B2 (es)
KR (1) KR20140105552A (es)
CN (1) CN104114552B (es)
AP (1) AP4017A (es)
AR (1) AR089143A1 (es)
AU (1) AU2012350751B2 (es)
BR (1) BR112014014184A2 (es)
CA (1) CA2858683A1 (es)
CL (1) CL2014001546A1 (es)
CO (1) CO6980657A2 (es)
CR (1) CR20140275A (es)
CU (1) CU20140068A7 (es)
CY (1) CY1116958T1 (es)
DK (1) DK2791136T3 (es)
DO (1) DOP2014000133A (es)
EC (1) ECSP14004812A (es)
ES (1) ES2550677T3 (es)
GT (1) GT201400111A (es)
HR (1) HRP20151103T1 (es)
HU (1) HUE025937T2 (es)
IL (1) IL232930A (es)
JO (1) JO3111B1 (es)
MA (1) MA35826B1 (es)
MX (1) MX2014007057A (es)
PE (1) PE20141597A1 (es)
PH (1) PH12014501319A1 (es)
PL (1) PL2791136T3 (es)
PT (1) PT2791136E (es)
RS (1) RS54288B1 (es)
RU (1) RU2632464C1 (es)
SG (1) SG11201402820SA (es)
SI (1) SI2791136T1 (es)
TN (1) TN2014000254A1 (es)
UA (1) UA112096C2 (es)
UY (1) UY34515A (es)
WO (1) WO2013087579A1 (es)
ZA (1) ZA201404031B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015000308A2 (pt) * 2012-07-10 2017-06-27 Bayer Pharma AG método para preparo de triazolopiridinas substituídas
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
PE20160156A1 (es) * 2013-06-11 2016-04-20 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas
EP3007692A1 (en) * 2013-06-11 2016-04-20 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
WO2015176981A1 (en) * 2014-05-19 2015-11-26 Basf Se Fluorescent organic light emitting elements having high efficiency
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
EP3233127A1 (de) 2014-12-15 2017-10-25 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern
CN105985241A (zh) * 2015-01-27 2016-10-05 邵阳学院 α-取代苯乙酸酯类化合物α-糖苷酶抑制作用及其应用
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
JP2018525334A (ja) 2015-06-23 2018-09-06 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｔｗｅａｋｒ抗体との抗体薬物複合体
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑
WO2018077944A2 (en) * 2016-10-27 2018-05-03 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
KR102556826B1 (ko) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
CN106831555B (zh) * 2017-01-22 2019-09-24 中国农业大学 吡啶酰胺类化合物及其制备方法与应用
KR102668688B1 (ko) 2018-07-23 2024-05-24 삼성디스플레이 주식회사 유기 발광 소자
CA3128946A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
KR102661468B1 (ko) 2019-02-15 2024-04-30 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 전자 장치
KR102897919B1 (ko) 2019-11-14 2025-12-09 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 장치
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
ES2549862T3 (es) 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
EP2178868A1 (en) 2007-07-18 2010-04-28 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
MX2010002312A (es) 2007-08-31 2010-03-18 Merck Serono Sa Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2222674B8 (en) 2007-11-27 2016-01-06 Cellzome Limited Amino triazoles as pi3k inhibitors
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
CN102317288A (zh) 2009-02-13 2012-01-11 佛维雅制药公司 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶
ES2547328T3 (es) 2009-04-29 2015-10-05 Bayer Intellectual Property Gmbh Imidazoquinoxalinas sustituidas
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
AU2011206635B2 (en) 2010-01-15 2015-01-22 Cellzome Limited Novel substituted triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
JP2011246389A (ja) * 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
US20140120087A1 (en) * 2011-04-21 2014-05-01 Bayer Intellectual Property Gmbh Triazolopyridines

Also Published As

Publication number Publication date
UY34515A (es) 2013-07-31
PT2791136E (pt) 2015-11-04
AU2012350751B2 (en) 2017-07-06
GT201400111A (es) 2015-11-30
HUE025937T2 (en) 2016-05-30
HRP20151103T1 (xx) 2015-11-20
DK2791136T3 (en) 2015-10-26
ES2550677T3 (es) 2015-11-11
WO2013087579A1 (en) 2013-06-20
JO3111B1 (ar) 2017-09-20
TN2014000254A1 (en) 2015-09-30
HK1203200A1 (en) 2015-10-23
CR20140275A (es) 2014-08-13
ZA201404031B (en) 2016-09-28
NZ625815A (en) 2016-07-29
DOP2014000133A (es) 2014-07-31
CY1116958T1 (el) 2017-04-05
CN104114552B (zh) 2016-12-28
AR089143A1 (es) 2014-07-30
MA35826B1 (fr) 2014-12-01
CO6980657A2 (es) 2014-06-27
AP4017A (en) 2017-01-28
CN104114552A (zh) 2014-10-22
US20150210683A1 (en) 2015-07-30
RS54288B1 (sr) 2016-02-29
CA2858683A1 (en) 2013-06-20
KR20140105552A (ko) 2014-09-01
PE20141597A1 (es) 2014-11-07
EP2791136B1 (en) 2015-07-29
EP2791136A1 (en) 2014-10-22
ECSP14004812A (es) 2015-11-30
MX2014007057A (es) 2014-08-08
PL2791136T3 (pl) 2015-12-31
IL232930A0 (en) 2014-08-03
JP6181664B2 (ja) 2017-08-16
PH12014501319A1 (en) 2014-09-08
SI2791136T1 (sl) 2015-11-30
IL232930A (en) 2016-07-31
US9663510B2 (en) 2017-05-30
AU2012350751A1 (en) 2014-06-26
RU2632464C1 (ru) 2017-10-05
SG11201402820SA (en) 2014-06-27
BR112014014184A2 (pt) 2017-06-13
CL2014001546A1 (es) 2014-10-24
UA112096C2 (uk) 2016-07-25
JP2015500308A (ja) 2015-01-05
AP2014007731A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
CU20120171A7 (es) Triazolopiridinas sustituidas
DOP2014000133A (es) Triazolopiridinas sustituidas
ECSP13013011A (es) Triazolopiridinas
DOP2012000150A (es) Triazolopiridinas
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CR20160016A (es) Pirazolpiridinas sustituidas
UY34854A (es) Inhibidores del transporte de glucosa
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY35602A (es) Compuestos nuevos para el tratamiento del cáncer
CL2013001945A1 (es) Compuestos derivados de pirazol de fórmulas (ia) o (ib), antagonistas de crth2; composiciones farmaceuticas que los contienen; combinaciones farmaceuticas; su uso en la prevencion y/o el tratamiento de trastornos inflamatorios, infecciosos e inmunorreguladores.
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
SV2010003773A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
CU20130141A7 (es) Triazolopiridinas
CL2011003355A1 (es) Compuestos derivados de alcoxi-carbonil-amino-alquinil-adenosina ; composición farmacéutica que los comprende; uso del compuesto en la preparación de un medicamento útil para tratar enfermedades autoinmunes, inflamatorias, alérgicas, infecciosas entre otras.
CL2011001916A1 (es) Uso de ezatiostat o una sal de el para el tratamiento del sindrome mielodisplasico; composicion farmaceutica que comprende a dicho compuesto ademas de lenalidomida; combinacion farmaceutica; kit farmaceutico.